Gilead Sciences, Inc.  

(Public, NASDAQ:GILD)   Watch this stock  
Find more results for GILD
-1.11 (-1.41%)
After Hours: 77.95 +0.09 (0.12%)
Sep 29, 7:54PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 77.75 - 79.34
52 week 76.67 - 111.11
Open 79.16
Vol / Avg. 7.62M/9.84M
Mkt cap 102.39B
P/E 6.86
Div/yield 0.47/2.41
EPS 11.35
Shares 1.32B
Beta 1.06
Inst. own 80%
Oct 25, 2016
Q3 2016 Gilead Sciences Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Sep 12, 2016
Gilead Sciences Inc at Morgan Stanley Global Healthcare Conference - Webcast
Sep 8, 2016
Gilead Sciences Inc at Wells Fargo Securities Healthcare Conference
Sep 7, 2016
Gilead Sciences Inc at Citi Biotech Conference
Jul 25, 2016
Q2 2016 Gilead Sciences Inc Earnings Call - Webcast
Jul 25, 2016
Q2 2016 Gilead Sciences Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '16) 2015
Net profit margin 44.97% 55.47%
Operating margin 58.36% 68.00%
EBITD margin - 71.35%
Return on average assets 28.70% 41.92%
Return on average equity 96.95% 106.64%
Employees 8,000 -
CDP Score - -


United States - Map
+1-650-5743000 (Phone)
+1-650-5789264 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Transcripts - SeekingAlpha


Gilead Sciences, Inc. is a research-based biopharmaceutical company. The Company focuses on the discovery, development and commercialization of medicines in areas of unmet medical need. The Company's principal areas of focus include human immunodeficiency virus (HIV), liver diseases, such as chronic hepatitis C virus infection and chronic hepatitis B virus infection, cardiovascular, hematology/oncology and inflammation/respiratory. Its HIV products include Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost and Vitekta. The Company's liver diseases products include Harvoni, Sovaldi, Viread and Hepsera. The Company's cardiovascular products include Letairis, Ranexa and Lexiscan/Rapiscan. Its oncology product is Zydelig. Its respiratory products include Cayston and Tamiflu. Its other products include AmBisome and Macugen. The Company's Nimbus Apollo program is a Phase II ready clinical program for NDI-010976 and related metabolic and liver diseases.

Officers and directors

John C. Martin Ph.D. Executive Chairman of the Board
Age: 64
Bio & Compensation  - Reuters
John F. Milligan Ph.D. Chief Executive Officer, Director
Age: 54
Bio & Compensation  - Reuters
Robin L. Washington Chief Financial Officer, Executive Vice President
Age: 53
Bio & Compensation  - Reuters
Kevin B. Young CBE Chief Operating Officer
Age: 55
Bio & Compensation  - Reuters
Norbert W. Bischofberger Ph.D. Executive Vice President - Research and Development, Chief Scientific Officer
Age: 60
Bio & Compensation  - Reuters
Kathleen Watson Executive Vice President - Human Resources
Bio & Compensation  - Reuters
Gregg H. Alton Executive Vice President - Corporate and Medical Affairs
Age: 50
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Martin Silverstein M.D. Executive Vice President - Strategy
Age: 48
Bio & Compensation  - Reuters
John F. Cogan Jr. Ph.D. Lead Independent Director
Age: 68
Bio & Compensation  - Reuters
Kelly A. Kramer Director
Bio & Compensation  - Reuters